Clinical trials: MTAP Deletion
Osteosarcoma, MTAP Deletion
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
MTAP deletion frequently occurs in osteosarcoma, and PRMT5 has been identified as a synthetic lethal target for cancers with homozygous deletion of the MTAP gene, making it a promising target for anti-tumor drug development.This…
- Conditions
- Osteosarcoma, MTAP Deletion, Immunohistochemistry
- Trial name
- NCT07593573
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Advanced Solid Tumors With MTAP Deletion
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101）
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have…
- Trial name
- NCT06796699
- Testing
- GH56 Capsule
- Where
- 25 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Malignant Peripheral Nerve Sheath Tumors, MPNST
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available…
- Trial name
- NCT07549022
- Testing
- BMS-986504
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ankit Mangla, MD